Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis

References

• Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. JCO. 2016;34(11):1256–1269. DOI:10.1200/JCO.2015.63.5904
   PubMed Web of Science ®Google Scholar
• Fu S, Wang M, Lairson DR, et al. Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: a comparative study between Texas and National SEER areas. Oncotarget. 2017;8(68):112516–112529.
   PubMedGoogle Scholar
• Fakhri B, Kahl B. Current and emerging treatment options for mantle cell lymphoma. Ther Adv Hematol. 2017;8(8):223–234.
   PubMed Web of Science ®Google Scholar
• Yang KK, Lucas E, Lesher B, et al. A systematic review of the epidemiology and economic burden of mantle cell lymphoma (MCL). Blood. 2019;134(Supplement_1):5831.
   Google Scholar
• Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113(4):791.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Lamy T, Walewski J, et al. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma. Br J Haematol. 2018;180(2):224–235. DOI:10.1111/bjh.15025
   PubMed Web of Science ®Google Scholar
• Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175–1179. DOI:10.1093/annonc/mdv111
   PubMed Web of Science ®Google Scholar
• Bond DA, Switchenko JM, Villa D, et al. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 2015;5(23):5179–5189. DOI:10.1182/bloodadvances.2021004765
   Google Scholar
• Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk‐stratification, and clinical management. Am J Hematol. 2017;92(8):806–813.
   PubMed Web of Science ®Google Scholar
• Hess G, Dreyling M, Oberic L, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol. 2022;00:1–11.
   Google Scholar
• Dreyling M, Shah B, Wu JJ, et al. Efficacy outcomes following treatment with Bruton tyrosine kinase inhibitors (BTKi) for relapsed/refractory mantle cell lymphoma (R/R MCL): a literature-based meta-analysis. Poster presented at ISPOR; May 2022; Washington, DC.
   Google Scholar
• National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: b-cell lymphomas. Version 5.2021. Sep 22, 2021.
   Google Scholar
• Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–2952. DOI:10.1182/blood-2013-11-531327
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520–531. DOI:10.1056/NEJMoa1200920
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). JCO. 2005;23:1984–1992.
   PubMed Web of Science ®Google Scholar
• Maddocks K. Update on mantle cell lymphoma. Blood. 2018;132(16):1647–1656.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–778. DOI:10.1016/S0140-6736(15)00667-4
   PubMed Web of Science ®Google Scholar
• Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211–1223. DOI:10.1056/NEJMoa1715519
   PubMed Web of Science ®Google Scholar
• Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688–3695. DOI:10.1200/JCO.2013.49.2835
   PubMed Web of Science ®Google Scholar
• Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867–4874. DOI:10.1200/JCO.2006.07.9665
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–667. DOI:10.1016/S0140-6736(17)33108-2
   PubMed Web of Science ®Google Scholar
• Monga N, Tam C, Garside J. Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: a systematic literature review. Crit Rev In Oncol/Hematol. 2021;158:103212.
   Google Scholar
• TECARTUS [package insert]. Santa Monica CA: Kite, A Gilead Company; 2021.
   Google Scholar
• JAYPIRCA [package insert]. (IN)polis IN: Lilly USA, LLC; 2023.
   Google Scholar
• Kabadi SM, Near A, Wada K, et al. Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States. Cancer Med. 2019;8(17):7174–7185.
   PubMed Web of Science ®Google Scholar
• Goyal RK, Nagar SP, Kabadi SM, et al. Adverse events, resource use and economic burden associated with mantle cell lymphoma: a real-world assessment of privately insured patients in the US. Leukemia & Lymphoma. Leukemia & Lymphoma. 2018;60(4):955–963. DOI:10.1080/10428194.2018.1509320
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med care. 2005;43(11):1130–1139. DOI:10.1097/01.mlr.0000182534.19832.83
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality. HCUP Chronic Condition Indicator. Healthcare Cost and Utilization Project (HCUP). [Accessed 2022 Oct 6]. Available at. https://www.hcup-us.ahrq.gov/toolssoftware/chronic_icd10/chronic_icd10.jsp
   Google Scholar
• Wade RL, Hu HX, Chen JY, et al. Increased treatment cost associated with mantle cell lymphoma disease progression. Haematologica. 2015;100:149.
   PubMed Web of Science ®Google Scholar
• Owen C, Berinstein NL, Chistofiedes A, et al. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26(2):e233–240.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Brown JR, Byrd JC, et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol. 2021;11. doi:10.3389/fonc.2021.720704.
   Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342. DOI:10.1056/NEJMoa1914347
   PubMed Web of Science ®Google Scholar
• Kumar A, Eyre TA, Lewis KL, et al. New Directions for Mantle Cell Lymphoma in 2022. Am Soc Clin Oncol Educ Book. 2022;42(42):614–628. DOI:10.1200/EDBK_349509
   Google Scholar
• National Cancer Institute. Financial burden of cancer care. Updated April 2022. Accessed May 2, 2022. https://www.progressreport.cancer.gov/after/economic_burden.
   Google Scholar